Literature DB >> 20373128

Inflammatory response to percutaneous coronary intervention in stable coronary artery disease.

Peter S Munk1, Unni M Breland, Pål Aukrust, Oyvind Skadberg, Thor Ueland, Alf I Larsen.   

Abstract

Percutaneous coronary intervention (PCI) can be regarded as a model for mechanical induced plaque rupture. The objective of this study was to evaluate the inflammatory response to PCI in stable coronary artery disease (CAD) by analysing plasma levels of a wide range of inflammatory mediators. Consecutively, we included 36 patients with stable angina pectoris after successful revascularization by PCI with implantation of a bare metal stent (BMS) or a drug eluting stent (DES). Patients were followed for 7 days with serial measurements of inflammatory mediators in plasma. C-reactive protein (CRP) and Pentraxin 3 showed a statistical significant early increase after PCI peaking at 3 days and 3 h, respectively. Vascular cell adhesion molecule-1 (VCAM-1) increased significantly with a peak at 3 days, while E-selectin showed a statistical significant gradual decrease. Markers of platelet mediated inflammation showed increasing (CD40 ligand) and decreasing (P-selectin) levels after PCI. While monocyte chemoattractant protein, CCL21 and CXCL16 increased rapidly in response to PCI, Interleukin-8, CCL19 and RANTES decreased. Patients with DES had significantly lower levels of VCAM-1 and RANTES compared to those with BMS. A femoral access site was associated with higher CRP levels than a radial access site. The use of glycoprotein-IIb/IIIa-inhibitors was associated with significantly higher CD40L and RANTES levels. Our findings underscore the complex nature of the inflammatory responses during PCI in stable CAD, and suggest that simultaneous measurements of several markers may be needed to characterize these PCI-related responses. The responses were only in a minor degree influenced by stent type, access site and the use of glycoprotein-IIb/IIIa-inhibitors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20373128     DOI: 10.1007/s11239-010-0471-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  26 in total

1.  Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation?

Authors:  Pal Aukrust; Jan Kristian Damas; Nils Olav Solum
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

2.  Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization.

Authors:  Jan K Damås; Camilla Smith; Erik Øie; Børre Fevang; Bente Halvorsen; Torgun Waehre; Agnes Boullier; Unni Breland; Arne Yndestad; Olga Ovchinnikova; Anna-Karin L Robertson; Wiggo J Sandberg; John Kjekshus; Kjetil Taskén; Stig S Frøland; Lars Gullestad; Göran K Hansson; Oswald Quehenberger; Pål Aukrust
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-12-14       Impact factor: 8.311

3.  Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.

Authors:  P Aukrust; F Müller; T Ueland; T Berget; E Aaser; A Brunsvig; N O Solum; K Forfang; S S Frøland; L Gullestad
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

4.  Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease.

Authors:  Ingebjørg Seljeflot; Serena Tonstad; Ingvar Hjermann; Harald Arnesen
Journal:  Atherosclerosis       Date:  2002-05       Impact factor: 5.162

5.  Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis.

Authors:  Nawsad Saleh; Per Tornvall
Journal:  Atherosclerosis       Date:  2006-11-28       Impact factor: 5.162

6.  A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins.

Authors:  Unni M Breland; Bente Halvorsen; Johanna Hol; Erik Øie; Gabrielle Paulsson-Berne; Arne Yndestad; Camilla Smith; Kari Otterdal; Ulf Hedin; Torgun Waehre; Wiggo J Sandberg; Stig S Frøland; Guttorm Haraldsen; Lars Gullestad; Jan K Damås; Gøran K Hansson; Pål Aukrust
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-02-14       Impact factor: 8.311

7.  Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells.

Authors:  Giuseppe Danilo Norata; Patrizia Marchesi; Angela Pirillo; Patrizia Uboldi; Giulia Chiesa; Virginia Maina; Cecilia Garlanda; Alberto Mantovani; Alberico Luigi Catapano
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-24       Impact factor: 8.311

8.  Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency.

Authors:  Jens Bollerslev; Thor Ueland; Anders P Jørgensen; Kristian J Fougner; Ragnhild Wergeland; Thomas Schreiner; Pia Burman
Journal:  Eur J Endocrinol       Date:  2006-04       Impact factor: 6.664

9.  CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.

Authors:  Olivier Dormond; Alan G Contreras; Esther Meijer; Dipak Datta; Evelyn Flynn; Soumitro Pal; David M Briscoe
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

10.  The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps.

Authors:  Sébastien Jaillon; Giuseppe Peri; Yves Delneste; Isabelle Frémaux; Andrea Doni; Federica Moalli; Cecilia Garlanda; Luigina Romani; Hugues Gascan; Silvia Bellocchio; Silvia Bozza; Marco A Cassatella; Pascale Jeannin; Alberto Mantovani
Journal:  J Exp Med       Date:  2007-03-26       Impact factor: 14.307

View more
  9 in total

1.  Microbial carriage state of peripheral blood dendritic cells (DCs) in chronic periodontitis influences DC differentiation, atherogenic potential.

Authors:  Julio Carrion; Elizabeth Scisci; Brodie Miles; Gregory J Sabino; Amir E Zeituni; Ying Gu; Adam Bear; Caroline A Genco; David L Brown; Christopher W Cutler
Journal:  J Immunol       Date:  2012-08-13       Impact factor: 5.422

2.  Influence of angioplasty and stenting on intracranial artery stenosis: preliminary results of high-resolution vessel wall imaging evaluation.

Authors:  Chia-Hung Wu; Chih-Ping Chung; Ting-Yi Chen; Kai-Wei Yu; Te-Ming Lin; Wei-An Tai; Chao-Bao Luo; Feng-Chi Chang
Journal:  Eur Radiol       Date:  2022-07-19       Impact factor: 7.034

3.  Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial.

Authors:  Binita Shah; Michael Pillinger; Hua Zhong; Bruce Cronstein; Yuhe Xia; Jeffrey D Lorin; Nathaniel R Smilowitz; Frederick Feit; Nicole Ratnapala; Norma M Keller; Stuart D Katz
Journal:  Circ Cardiovasc Interv       Date:  2020-04-16       Impact factor: 6.546

Review 4.  Colchicine in the Management of Acute and Chronic Coronary Artery Disease.

Authors:  Nadia Bouabdallaoui; Jean-Claude Tardif
Journal:  Curr Cardiol Rep       Date:  2021-07-16       Impact factor: 2.931

5.  Serum Levels of IL-1 β , IL-6, TGF- β , and MMP-9 in Patients Undergoing Carotid Artery Stenting and Regulation of MMP-9 in a New In Vitro Model of THP-1 Cells Activated by Stenting.

Authors:  Rongrong Zhang; Fan Jiang; Cindy Si Chen; Tianzhu Wang; Jinzhou Feng; Tao Tao; Xinyue Qin
Journal:  Mediators Inflamm       Date:  2015-05-31       Impact factor: 4.711

6.  Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation.

Authors:  Liu Haibo; Guo Xiaofang; Wang Chunming; Yuan Jie; Chen Guozhong; Zhang Limei; Cao Yong; Fang Yu; Bao Yingchun; Yu Wangjun; Ge Junbo
Journal:  Mediators Inflamm       Date:  2014-11-24       Impact factor: 4.711

7.  Endothelial cell activation is attenuated by everolimus via transcriptional and post-transcriptional regulatory mechanisms after drug-eluting coronary stenting.

Authors:  Zsolt Fejes; Zsolt Czimmerer; Tibor Szük; Szilárd Póliska; Attila Horváth; Enikő Balogh; Viktória Jeney; Judit Váradi; Ferenc Fenyvesi; György Balla; István Édes; József Balla; János Kappelmayer; Béla Nagy
Journal:  PLoS One       Date:  2018-06-11       Impact factor: 3.240

Review 8.  Pentraxin 3 in Cardiovascular Disease.

Authors:  Giuseppe Ristagno; Francesca Fumagalli; Barbara Bottazzi; Alberto Mantovani; Davide Olivari; Deborah Novelli; Roberto Latini
Journal:  Front Immunol       Date:  2019-04-17       Impact factor: 7.561

9.  Pentraxin 3 might be better prognostic serum marker than IL-6, IL-10, and high-sensitivity C-reactive protein for major adverse cardiovascular events in patients with ST-elevation myocardial infarction after bare-metal stent implantation.

Authors:  Farid Ljuca; Bahrudin Hadžiefendić; Elmir Jahić; Nijaz Tihić; Saša Lukić
Journal:  Saudi Med J       Date:  2019-12       Impact factor: 1.484

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.